| Literature DB >> 29544497 |
Christoph Ihle1, Christoph Weiß1, Gunnar Blumenstock2, Ulrich Stöckle1, Björn Gunnar Ochs3, Christian Bahrs1, Andreas Nüssler4, Anna Janine Schreiner1.
Abstract
BACKGROUND: Being at risk for malnutrition can be observed among hospitalized patients of all medical specialties. There are only few studies in arthroplasty dealing with defining and assessing malnutrition as such a potentially risk. This study aims to identify the risk for malnutrition following primary (pAP) and revision arthroplasty (rAP) (1) using non-invasive interview based assessment tools and to analyze effects on clinical outcome (2) and quality of life (3).Entities:
Keywords: Arthroplasty; Interview based assessment; MNA; Malnutrition; NRS 2002; SF-MNA
Mesh:
Year: 2018 PMID: 29544497 PMCID: PMC5856317 DOI: 10.1186/s12891-018-2004-z
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Fig. 1Patient flow chart according to STROBE standards
Fig. 2Health related quality of life in primary and revision arthroplasty comparing different nutritional status. Part 1 and 2: Figure two part one and two describe the values of health related quality of life at hospital admission and six months following surgery in all eight SF-36 dimensions comparing primary arthroplasty (pAP), revision arthroplasty (rAP) and the whole study population (overall). A pre- to postoperative improvement of HRQL can be found according to all eight dimensions. Part 3 and 4: Part three and four show the eight SF-36 dimensions of the whole study population according to all three nutritional scores comparing the nutritional status (Malnutrition vs. No Malnutrition) at hospital admission and six months following surgery. HRQL is preoperatively decreased. Patients being at risk for malnutrition before surgery show statistically significant lower values in physical (PF, RP, BP, GH) as well as mental dimensions (SF, RE, MH). In comparison to the preoperative SF-36 results, the values of the patients with risk for malnutrition are adjusting to the values of the patients with a regular nutritional status. PF: Physical Functioning; RP: Role Physical; BP: Bodily Pain; GH: General Health; VT: Vitality; SF: Social Functioning; RE: Role Emotional; MH: Mental Health; pAP: Primary Arthroplasty; rAP: Revision Arthroplasty; HRQL: Health related quality of life
Length of hospital stay (LOS) and Mobilization in relation to NRS, SF-MNA and MNA
| NRS | ||||
| Risk for malnutrition / no risk | + | – | p | |
| all | Hospitalization (LOS, days) | 14.5 ± 5.3 | 12.5 ± 3.2 | 0.006 |
| all | Mobilization (days after surgery) | 2.1 ± 1.0 | 1.7 ± 0.7 | 0.012 |
| SF-MNA | T1 | |||
| Risk for malnutrition / no risk | + | – | p | |
| all | Hospitalization (LOS, days) | 13.7 ± 3.9 | 12.4 ± 3.5 | 0.001 |
| all | Mobilization (days after surgery) | 1.8 ± 0.9 | 1.7 ± 0.7 | 0.267 |
| MNA | T1 | |||
| Risk for malnutrition / no risk | + | – | p | |
| all | Hospitalization (LOS, days) | 13.9 ± 4.3 | 12.3 ± 3.3 | 0.001 |
| all | Mobilization (days after surgery) | 1.9 ± 1.0 | 1.7 ± 0.6 | 0.189 |
Incidence of major (grey) and minor adverse events in primary and revision arthroplasty
| all | pAP | rAP | ||||
|---|---|---|---|---|---|---|
| No adverse events T1 | 62.1% (218) | 66.4% (188) | 44.1% (30) | |||
| No adverse events T2 | 89.1% (219) | 91.2% (186) | 78.6% (33) | |||
| Adverse events T1 | 37.9% (133) | 33.6% (95) | 55.9% (38) | |||
| Adverse events T2 | 10.9% (27) | 8.8% (18) | 21.4% (9) | |||
| Infection T1 | 3 / 351 | 0.9% | 1 / 283 | 0.4% | 2 / 68 | 2.9% |
| Infection T2 | 8 / 246 | 3.3% | 5 / 204 | 2.5% | 3 / 42 | 7.1% |
| Wound healing disorder T1 | 3 / 351 | 0.9% | 2 / 283 | 0.7% | 1 / 68 | 1.5% |
| Wound healing disorder T2 | 2 / 246 | 0.8% | 2 / 204 | 1.0% | 0 / 42 | 0.0% |
| Further operations T1 | 5 / 351 | 1.4% | 2 / 283 | 0.7% | 3 / 68 | 4.4% |
| Further operations T2 | 1 / 246 | 0.4% | 1 / 204 | 0.5% | 0 / 42 | 0.0% |
| Thrombosis T1 | 1 / 351 | 0.3% | 0 / 283 | 0.0% | 1 / 68 | 1.5% |
| Thrombosis T2 | 2 / 246 | 0.8% | 2 / 204 | 1.0% | 0 / 42 | 0.0% |
| Minor adverse events T1 | 121 / 351 | 34.5% | 90 / 283 | 31.8% | 31 / 68 | 45.6% |
| Minor adverse events T2 | 14 / 246 | 5.7% | 8 / 204 | 3.9% | 6 / 42 | 14.3% |
All Adverse events in relation to NRS, SF-MNA and MNA
| NRS | T1 | T2 | |||||
| Risk for malnutrition / no risk | + | – | p | + | – | p | |
| all | Adverse events | 53.2% (25) | 35.5% (108) | 22.6% (7) | 9.3% (20) | ||
| No adverse events | 46.8% (22) | 64.5% (196) | 0.02 | 77.4% (24) | 90.7% (195) | 0.03 | |
|
|
|
|
|
| |||
| pAP | Adverse events | 40.6% (13) | 32.7% (82) | 13.6% (3) | 8.2% (15) | ||
| No adverse events | 59.4% (19) | 67.3% (169) | 0.37 | 86.4% (19) | 91.8% (167) | 0.40 | |
|
|
|
|
|
| |||
| rAP | Adverse events | 80.0% (12) | 49.1% (26) | 44.4% (4) | 15.2% (5) | ||
| No adverse events | 20.0% (3) | 50.9% (27) | 0.03 | 55.6% (5) | 84.8% (28) | 0.06 | |
|
|
|
| 9 |
| |||
| SF-MNA | T1 | T2 | |||||
| Risk for malnutrition / no risk | + | – | p | + | – | p | |
| all | Adverse events | 46.4% (39) | 35.2% (94) | 17.9% (10) | 8.9% (17) | ||
| No adverse events | 53.6% (45) | 64.8% (173) | 0.06 | 82.1% (46) | 91.1% (173) | 0.06 | |
|
|
|
|
|
| |||
| pAP | Adverse events | 39.4% (26) | 31.8% (69) | 12.8% (6) | 7.6% (12) | ||
| No adverse events | 60.6% (40) | 68.2% (148) | 0.25 | 87.2% (41) | 92.3% (145) | 0.28 | |
|
|
|
|
|
| |||
| rAP | Adverse events | 72.2% (13) | 50.0% (25) | 44.4% (4) | 15.2% (5) | ||
| No adverse events | 27.8% (5) | 50.0% (25) | 0.10 | 55.6% (5) | 84.8% (28) | 0.06 | |
|
|
|
|
|
| |||
| MNA | T1 | T2 | |||||
| Risk for malnutrition / no risk | + | – | p | + | – | p | |
| all | Adverse events | 49.0% (47) | 33.7% (86) | 17.5% (11) | 8.7% (16) | ||
| No adverse events | 51.0% (49) | 66.3% (169) | 0.01 | 82.5% (52) | 91.3% (167) | 0.06 | |
|
|
|
|
|
| |||
| pAP | Adverse events | 43.2% (33) | 29.9% (62) | 15.1% (8) | 6.6% (10) | ||
| No adverse events | 56.8% (43) | 70.1% (145) | 0.03 | 8.9% (45) | 93.4% (141) | 0.06 | |
|
|
|
|
|
| |||
| rAP | Adverse events | 70.0% (14) | 50.0% (24) | 30.0% (3) | 18.8% (6) | ||
| No adverse events | 30.0% (6) | 50.0% (24) | 0.13 | 70.0% (7) | 81.2% (26) | 0.45 | |
|
|
|
|
|
| |||